Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.75 |
| ▸ | DRD3 | P35462 | 4/20 | 0.75 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | DRD4 | P21917 | 4/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673255 | 0.93 | SIGMAR1 (0.85) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL12896039 | 0.92 | SIGMAR1 (0.87) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL1887377 | 0.90 | SIGMAR1 (0.87) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL1887858 | 0.89 | DRD3 (0.74) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL1887002 | 0.89 | SIGMAR1 (0.84) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL1883345 | 0.87 | SIGMAR1 (0.74) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL1890221 | 0.86 | SIGMAR1 (0.83) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL8285664 | 0.86 | SIGMAR1 (1.00) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL8285657 | 0.85 | SIGMAR1 (1.00) | SIGMAR1DRD3TMEM97DRD2DRD4 | |
| SCHEMBL12673209 | 0.84 | SIGMAR1 (0.83) | SIGMAR1DRD3TMEM97DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8506927-B2 | Pegylated fluorobenzamide analogues, their synthesis and use in diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120171119-A1 | PEGYLATED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| US-8193360-B2 | Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110230662-A1 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| US-7947838-B2 | Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947838-B2 | Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100150836-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150836-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2164327-A2 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7659400-B2 | Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2009025914-A2 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20080107599-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY OF ST. LOUIS | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171119-A1 | PEGYLATED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | TMEM97, SIGMAR1, SFN | SIGMAR1 2/4885DRD3 1235/4885TMEM97 1/4885 |
| US-20080107599-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | TMEM97, SIGMAR1, SFN | SIGMAR1 2/4885DRD3 562/4885TMEM97 1/4885 |
| US-20100150836-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | TMEM97, SIGMAR1, SFN | SIGMAR1 2/4885DRD3 562/4885TMEM97 1/4885 |
| US-20110230662-A1 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | TMEM97, SIGMAR1, SFN | SIGMAR1 2/4885DRD3 487/4885TMEM97 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.